The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
News|Articles|June 2, 2017
Phenomenex Opens New Manufacturing Facility
Author(s)Pharmaceutical Technology Editors
Phenomenex opened a new manufacturing and development facility in CA for the company’s gas chromatography columns.
Advertisement
On May 30, 2017, Phenomenex announced the opening of a new manufacturing and development facility dedicated to the company’s gas chromatography columns, marketed under the Zebron brand name. The 15,000-ft2 facility is located in El Dorado Hills, CA, a suburb of Sacramento. The new facility includes organic synthesis, R&D, and analytical labs. The new location supports twice the production capacity and will improve Phenomenex’s logistics and delivery speeds. In a
Source:
Advertisement
Related to this article
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
Jaenisch, Muraru, and Pandey debate whether AI "slop" is infiltrating pharma SOPs and deviation reports and who should catch it first.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
2
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech AI Pulse Check: Fixing AI Slop at the Source
5